- Lung Cancer Basics
Additional $12M Secured For Federally-Funded Lung Cancer Research
Thursday, May 4, 2017 — Today, The Omnibus FY17 Appropriations bill was approved in the Senate by a vote of 79-18 after passing out of the House. The $1.07 trillion dollar bill includes 11 of the 12 spending bills wrapped into one package to fund federal programs.
After months of operating under a continuing resolution, the bill finalizes increases to federal cancer and health programs highlighted by an additional $12 million for the Lung Cancer Research Program within the FY17 Department of Defense (DOD) Appropriations Bill under the Congressionally Directed Medical Research Program (CDMRP).
Additionally, the bill allocates $34.084 billion for the National Institutes of Health (NIH). This amount includes $5.689 billion in FY17 for the National Cancer Institute (NCI), which will cover funding for 21st Century Cures specifically to support the Beau Biden Cancer Moonshot Initiative. The final program level for the Centers for Disease Control and Prevention (CDC) is at $7.165 billion, which maintains all the CDC cancer control programs. And finally, the Food and Drug Administration (FDA) receives an appropriation of $2.77 billion. This FY17 budget agreement is in line with LCA’s FY17 Appropriations request for increases in cancer and health research funding.
LCA was responsible for establishing the dedicated Lung Cancer Research Program pipeline in 2008 and has consistently secured funding for it every fiscal year since its establishment. The $12 million now brings the total 8 year funding to well over $100M. The Lung Cancer Research Program at CDMRP has played a critical role in supporting high-impact, innovative lung cancer research within the military and general public in several areas including risk assessment, prevention, early detection, diagnosis, treatment, survivorship and outcomes.
Details about the CDMRP can be viewed here.